Health
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
MINNEAPOLIS, May 19, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study.
About this update from Diamedica Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/d4b4ec25abcbe9aa7e6c8c4c79c73660"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hzfCamW_HKgygud4bhW12Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d4b4ec25abcbe9aa7e6c8c4c79c73660","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LNcg6PzULFsg8YiE6v1PUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d4b4ec25abcbe9aa7e6c8c4c79c73660","width":1200,"height":379}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central","length":97,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":97,"olType":false},{"type":"text","content":"MINNEAPOLIS, May 19, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study.","length":470,"tagName":"p"},{"type":"text","content":"The webinar will feature Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Susan Walker, MD, PhD (The University of Melbourne), and Prof. Baha Sibai, MD (University of Texas) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. This will be followed by the Phase 2, proof-of-concept, clinical trial design and endpoints of DM199 in PE. DM199, through enhancing the body’s natural ability to produce nitric oxide, prostacyclin and endothelium-derived hyper polarizing factor, has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.","length":741,"tagName":"p"},{"type":"text","content":"A live question and answer session will ...